In April of this year, Takeda Pharmaceutical, Japan’s largest drug company purchased Millennium Pharmaceuticals, one of the earliest American genomics companies for nearly $9 billion providing Takeda an entry into the cancer-drug market. During this off-the-record discussion, topics will include:
- Important criteria each company sought in a strategic partner
- Communicating effectively through cultural differences
- Lessons learned during the due diligence process
- Approach for successful integration of the two companies
Presenters included:
- Gabor Garai, Co-Chair, Life Sciences Industry Team, Foley
- Dr. Daniel Curran, Vice President, Corporate Development, Millennium Pharmaceuticals Inc.
- Catherine Sazdanoff, Vice President, Global Licensing, Takeda Pharmaceuticals North America, Inc.
Related Insights
August 1, 2025
Foley Ignite
Is an IPO Window Opening for H2 2025?
Executive Summary The IPO market is showing encouraging signs of recovery in 2025, with 201 companies going public year-to-date compared…
August 1, 2025
Foley Viewpoints
Maryland Insurance Administration Proposes to Revise Regulation Governing Disclosures of Credit Scoring Use in Private Passenger Automobile Insurance Rating
The Maryland Insurance Administration recently proposed to revise a regulation regarding the use and disclosure of credit history in underwriting and rate making for personal automobile policies.
July 31, 2025
Foley Viewpoints
Tsunamis and the National Flood Insurance Program
On July 30, an 8.8 magnitude earthquake occurred off of Russia’s Eastern Kamchatka coast, subsequently triggering tsunami warnings in, among other places, Japan and Hawaii.